ACCELERATED PRECOMPUTATION OF REDUCED DEFORMABLE MODELS

    公开(公告)号:US20180247158A1

    公开(公告)日:2018-08-30

    申请号:US15757261

    申请日:2016-09-02

    Applicant: STC.UNM

    Inventor: Yin Yang

    CPC classification number: G06K9/6247 G06F17/16 G06K9/6214 G06T13/20 G06T17/20

    Abstract: Technologies are disclosed for precomputation of reduced deformable models. In such precomputation, a Krylov subspace iteration may be used to construct a series of inertia modes for an input mesh. The inertia modes may be condensed into a mode matrix. A set of cubature points may be sampled from the input mesh, and cubature weights of the set of cubature points may be calculated for each of the inertia modes in the mode matrix. A training dataset may be generated by iteratively adding training samples to the training dataset until a training error metric converges, wherein each training sample is generated from an inertia mode in the mode matrix and corresponding cubature weights. The reduced deformable model may be generated, including inertia modes in the training dataset and corresponding cubature weights.

    Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same

    公开(公告)号:US10022327B2

    公开(公告)日:2018-07-17

    申请号:US14970998

    申请日:2015-12-16

    Abstract: The present invention is directed to protocells for specific targeting of hepatocellular and other cancer cells which comprise a nanoporous silica core with a supported lipid bilayer; at least one agent which facilitates cancer cell death (such as a traditional small molecule, a macromolecular cargo (e.g. siRNA or a protein toxin such as ricin toxin A-chain or diphtheria toxin A-chain) and/or a histone-packaged plasmid DNA disposed within the nanoporous silica core (preferably supercoiled in order to more efficiently package the DNA into protocells) which is optionally modified with a nuclear localization sequence to assist in localizing protocells within the nucleus of the cancer cell and the ability to express peptides involved in therapy (apoptosis/cell death) of the cancer cell or as a reporter, a targeting peptide which targets cancer cells in tissue to be treated such that binding of the protocell to the targeted cells is specific and enhanced and a fusogenic peptide that promotes endosomal escape of protocells and encapsulated DNA. Protocells according to the present invention may be used to treat cancer, especially including hepatocellular (liver) cancer using novel binding peptides (c-MET peptides) which selectively bind to hepatocellular tissue or to function in diagnosis of cancer, including cancer treatment and drug discovery.

    SYSTEM AND METHODS FOR DETECTING RIBOSOME INHIBITION

    公开(公告)号:US20180156783A1

    公开(公告)日:2018-06-07

    申请号:US15577809

    申请日:2016-06-02

    Applicant: STC.UNM

    CPC classification number: G01N33/5076 C12Q1/6897 G01N33/533

    Abstract: This disclosure describes a cell genetically modified to detect ribosome inhibition in the cell and methods involving such a cell. Generally, the genetically-modified cell includes an aminoglycoside-sensitive orthogonal 16S rRNA (O-16S) coding region bearing a mutated anti-Shine-Dalgarno (O-ASD) sequence, a repressor/operator system, and a polynucleotide encoding a detectable reporter under transcriptional control of the repressor/operator system. The repressor/operator system includes a coding region that encodes a transcriptional regulator and having an orthogonal SD (O-SD) sequence complementary to the 16S rRNA O-ASD sequence. The operator sequence, which is repressable by the transcriptional regulator, is operably linked to the polynucleotide encoding a detectable reporter.

Patent Agency Ranking